Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:41:58.621Z.
Calculation as of: 2026-10-06T13:41:58.621Z.
Quote observation: 2026-10-06T13:39:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$6.73M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.85M
Price/FCF Ratio
N/A
TTM Avg
2104.37
3Y Avg
2470.51
5Y Avg
5857.68
Market Cap
$7.44M
Price/FCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
Market Cap
$6.52M
Price/FCF Ratio
N/A
TTM Avg
1251.36
3Y Avg
3596.79
5Y Avg
3596.79
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $6.73M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | N/A | 2104.37 | 2470.51 | 5857.68 |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | N/A | 6.05 | 13.36 | 13.36 |
| Aclarion, Inc. (ACON)vs › | $6.80M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.44M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $7.03M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.52M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.65M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | N/A | 1251.36 | 3596.79 | 3596.79 |
| Biomerica, Inc. (BMRA)vs › | $6.42M | N/A | 129.84 | 129.84 | 129.84 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
